Author: Leah Kosyakovsky

BRIDGE-TIMI 73a Trial: Olezarsen significantly reduces triglyceride levels among patients with hypertriglyceridemia and elevated CV risk
ACC 2024, News

BRIDGE-TIMI 73a Trial: Olezarsen significantly reduces triglyceride levels among patients with hypertriglyceridemia and elevated CV risk

Key Points: Olezarsen is an antisense oligonucleotide which targets messenger RNA for apolipoprotein C-III (APOC3), a lipoprotein which up-regulates triglyceride... Read more.
ACC 2024, News

Mandibular Advancement Device (MAD) Therapy Non-Inferior to CPAP for Blood Pressure Reduction In OSA And High CV Risk: The CRESCENT Trial

Key Points: Hypertension (HTN) guidelines recommend treating obstructive sleep apnea (OSA) in such patients, though data on BP reduction for mandibular advancement... Read more.
Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli
ACC 2024, News

Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli

Key Points:   The SMART trial is the first randomized non-inferiority trial to test a head-to-head comparison between the Medtronic Evolut valve (Evolut PRO/PRO+/FX)... Read more.
A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2
ACC 2024, Hypertension, News

A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2

Key Points:  Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT) synthesis by RNA interference. The KARDIA-1 trial showed that subcutaneous... Read more.
BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk
ACC 2024, News

BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk

Key Points: The majority of US adults at elevated risk for ASCVD do not engage in the recommended amount of daily exercise. Behavioral economic strategies to incentivize... Read more.
STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM
ACC 2024, News

STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM

Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight and improve HF-related symptoms among individuals... Read more.
ACC 2024, News

Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)

Key Points:   TELE-ACS evaluates the use of telemedicine strategies to reduce hospital readmission rates in patients with a recent history of acute coronary syndrome ... Read more.
An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial
ACC 2024, News

An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial

Key Points: Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve sufficiently reduced low-density lipoprotein cholesterol (LDL-C) levels... Read more.